Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

Prior treatment

• Known history of allergy to the investigational drug;
• Inability to take oral medication;

Other illness

• Combined with uncontrolled active infections (including bacterial, fungal or viral infections);
• Combined with uncontrolled major organ dysfunction: cardiac insufficiency, decompensated liver insufficiency, moderate/severe renal insufficiency, etc.;

Other

• Resistance to azacytidine, azacitidine, Venetoclax;
• Participating in other clinical studies that affect the main purpose of this study; Patients deemed unsuitable for participation in this study.

• Diagnosed with AML (the diagnostic criteria refer to WHO2022 standard, non-APL), and have not received systemic anti-leukemia therapy (except hydroxyurea, low-dose cytarabine and other tumor reduction pretreatments);
• Age ≥18 years old;
• ECOG≤4;
• The fertile woman agrees to use effective contraception during the treatment period and up to 3 months after the end of the treatment; Sign the informed consent form.